Page 115 - Read Online

Abaji et al. Cancer Drug Resist 2019;2:242-55 I http://dx.doi.org/10.20517/cdr.2018.24 Page 253

allergies. Blood 2014;124:1266-76.
5. Mei L, Ontiveros EP, Griffiths EA, Thompson JE, Wang ES, et al. Pharmacogenetics predictive of response and toxicity in acute
lymphoblastic leukemia therapy. Blood Rev 2015;29:243-9.
6. Alachkar H, Fulton N, Sanford B, Malnassy G, Mutonga M, et al. Expression and polymorphism (rs4880) of mitochondrial superoxide
dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. Pharmacogenomics J
2017;17:274-9.
7. Paugh SW, Stocco G, Evans WE. Pharmacogenomics in pediatric leukemia. Curr Opin Pediatr 2010;22:703-10.
8. Lopez-Santillan M, Iparraguirre L, Martin-Guerrero I, Gutierrez-Camino A, Garcia-Orad A. Review of pharmacogenetics studies
of L-asparaginase hypersensitivity in acute lymphoblastic leukemia points to variants in the GRIA1 gene. Drug Metab Pers Ther
2017;32:1-9.
9. Kutszegi N, Semsei AF, Gezsi A, Sagi JC, Nagy V, et al. Subgroups of paediatric acute lymphoblastic leukaemia might differ
significantly in genetic predisposition to asparaginase hypersensitivity. PLoS One 2015;10:e0140136.
10. Ben Tanfous M, Sharif-Askari B, Ceppi F, Laaribi H, Gagne V, et al. Polymorphisms of asparaginase pathway and asparaginase-related
complications in children with acute lymphoblastic leukemia. Clin Cancer Res 2015;21:329-34.
11. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
12. Schmiegelow K, Muller K, Mogensen SS, Mogensen PR, Wolthers BO, et al. Non-infectious chemotherapy-associated acute toxicities
during childhood acute lymphoblastic leukemia therapy. F1000Res 2017;6:444.
13. Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
Blood 2012;120:1165-74.
14. Cheok MH, Pottier N, Kager L, Evans WE. Pharmacogenetics in acute lymphoblastic leukemia. Semin Hematol 2009;46:39-51.
15. Wolthers BO, Frandsen TL, Abrahamsson J, Albertsen BK, Helt LR, et al. Asparaginase-associated pancreatitis: a study on phenotype
and genotype in the NOPHO ALL2008 protocol. Leukemia 2017;31:325-32.
16. Zhang G, Nebert DW. Personalized medicine: genetic risk prediction of drug response. Pharmacol Ther 2017;175:75-90.
17. Abaji R, Krajinovic M. Thiopurine S-methyltransferase polymorphisms in acute lymphoblastic leukemia, inflammatory bowel disease
and autoimmune disorders: influence on treatment response. Pharmgenomics Pers Med 2017;10:143-56.
18. Rousseau J, Gagne V, Labuda M, Beaubois C, Sinnett D, et al. ATF5 polymorphisms influence ATF function and response to treatment
in children with childhood acute lymphoblastic leukemia. Blood 2011;118:5883-90.
19. Chen SH, Yang W, Fan Y, Stocco G, Crews KR, et al. A genome-wide approach identifies that the aspartate metabolism pathway
contributes to asparaginase sensitivity. Leukemia 2011;25:66-74.
20. Aslanian AM, Kilberg MS. Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant
MOLT-4 human leukaemia cells. Biochem J 2001;358:59-67.
21. Sugimoto K, Suzuki HI, Fujimura T, Ono A, Kaga N, et al. A clinically attainable dose of L-asparaginase targets glutamine addiction in
lymphoid cell lines. Cancer Sci 2015;106:1534-43.
22. Pui CH, Thiel E. Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Semin
Oncol 2009;36:S2-16.
23. Tram Henriksen L, Gottschalk Hojfeldt S, Schmiegelow K, Frandsen TL, Skov Wehner P, et al. Prolonged first-line PEG-asparaginase
treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
Pediatr Blood Cancer 2017;64.
24. Nguyen HA, Su Y, Zhang JY et al. A Novel l-Asparaginase with low l-Glutaminase Coactivity Is Highly Efficacious against Both T- and
B-cell Acute Lymphoblastic Leukemias In Vivo. Cancer Res 2018;78: 1549-60.
25. Chen SH, Pei D, Yang W, Cheng C, Jeha S, et al. Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase
hypersensitivity. Clin Pharmacol Ther 2010;88:191-6.
26. Kawedia JD, Kaste SC, Pei D, Panetta JC, Cai X, et al. Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of
osteonecrosis in children with acute lymphoblastic leukemia. Blood 2011;117:2340-7; quiz 556.
27. Kawedia JD, Liu C, Pei D, Cheng C, Fernandez CA, et al. Dexamethasone exposure and asparaginase antibodies affect relapse risk in
acute lymphoblastic leukemia. Blood 2012;119:1658-64.
28. Liu C, Janke LJ, Kawedia JD, Ramsey LB, Cai X, et al. Asparaginase potentiates glucocorticoid-induced osteonecrosis in a mouse
model. PLoS One 2016;11:e0151433.
29. Castro-Pastrana LI, Ghannadan R, Rieder MJ, Dahlke E, Hayden M, et al. Cutaneous adverse drug reactions in children: an analysis of
reports from the Canadian Pharmacogenomics Network for Drug Safety (CPNDS). J Popul Ther Clin Pharmacol 2011;18:e106-20.
30. Fernandez CA, Smith C, Yang W, Mullighan CG, Qu C, et al. Genome-wide analysis links NFATC2 with asparaginase hypersensitivity.
Blood 2015;126:69-75.
31. Rajic V, Debeljak M, Goricar K, Jazbec J. Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the
treatment of childhood acute lymphoblastic leukemia. Leuk Lymphoma 2015;56:3103-8.
32. Kutszegi N, Yang X, Gezsi A et al. HLA-DRB1*07:01-HLA-DQA1*02:01-HLA-DQB1*02:02 haplotype is associated with a high risk
of asparaginase hypersensitivity in acute lymphoblastic leukemia. Haematologica 2017;102:1578-86.
33. Hojfeldt SG, Wolthers BO, Tulstrup M et al. Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according
to NOPHO ALL2008. Br J Haematol 2019;184: 405-17.
34. Kumar S, Ooi CY, Werlin S, Abu-El-Haija M, Barth B, et al. Risk factors associated with pediatric acute recurrent and chronic
pancreatitis: lessons from INSPPIRE. JAMA Pediatr 2016;170:562-9.